Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

And while Pfizer is making big bets on cancer research, its CEO said he’s not taking his foot off the pedal with investment in vaccines either, despite a “very big gap” between the company ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of ...

Advanced colon cancer patients lived twice as long with a Pfizer combo therapy, trial finds Patients who got the combination treatment lived, on average, about 30 months, compared with about 15 ...

This Pfizer drug is specifically designed to block enzymes with a mutation called BRAF V600E. It was first approved in 2018 for treating advanced melanoma with that genetic signature. presented by ...

And while Pfizer is making big bets on cancer research, its CEO said he’s not taking his foot off the pedal with investment in vaccines either, despite a “very big gap” between the company and HHS – ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird ...

Patrick T. Fallon/AFP/Getty Images via CNN Newsource CEO Dr. Albert Bourla says Pfizer has some "very real concerns" about new requirements for clinical trials of Covid-19 vaccines.

“MRNA probably is the most utilized vaccine in the history of humanity,” Pfizer CEO Dr. Albert Bourla said Friday, noting that there have been about 1.5 billion mRNA vaccine doses against ...

Anna Solomon is Wallpaper*’s Digital Staff Writer, working across all of Wallpaper.com’s core pillars, with special interests in interiors and fashion. Before joining the team in 2025, she was Senior ...

Pfizer Inc. PFE-N is a stock I’ve been selling aggressively in recent months after holding it in my client portfolios for about 20 years. I got frustrated with the stock.